BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bemdaneprocel (MSK-DA01) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bemdaneprocel (MSK-DA01)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06944522-1768@assetmemo.bio
DTSTAMP:20261121T005803Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Bemdaneprocel (MSK-DA01): Phase 3 readout est. (NCT06944522)
DESCRIPTION:Bemdaneprocel (MSK-DA01)\, phase 3\, Parkinson's Disease.\nStud
 y: A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adul
 ts Who Have Parkinson's Disease\nEstimated primary completion: October 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bemdaneprocel-msk-
 da01#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06944522
URL:https://assetmemo.bio/drug/bemdaneprocel-msk-da01#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
